More pulmonary arterial hypertension (PAH) patients were able to achieve complete daily inhalations after switching to a more concentrated formulation of Ventavis (iloprost), which also reduced the duration of each treatment administration, an observational study reports. The study looked at the inhalation behavior of PAH patients who were switched from…
News
Evaluation of Midkine (MDK) and Follistatin-like 3 (FSTL3) protein levels in the blood can help identify patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH), researchers suggest. The study, “Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis” was published in the journal…
Intravenous treatment with the approved heart failure medicine milrinone leads to significant improvements in heart structure and function in patients with mild-to-moderate pulmonary hypertension (PH) due to left heart disease, a study has found.” The report titled “Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients…
Mylan recently introduced a formulation of 20 mg tadalafil tablets, the first generic version of Eli Lilly‘s Adcirca, in the United States for patients with pulmonary arterial hypertension (PAH). The U.S. Food and Drug Administration gave Mylan final approval for its abbreviated new drug application for tadalafil,…
For patients with pulmonary hypertension (PH) who have undergone nonheart surgeries, self-reporting of walking and stair climbing ability can predict the risk of postsurgical complications, a study found. Researchers say this simple and noninvasive assessment can help identify PH patients at high risk of complications,…
Treatment with Phps-1, which inhibits a protein called Shp2, was able to alleviate specific symptoms of pulmonary arterial hypertension (PAH) in a rat model, suggesting that Shp2 may be a potential therapeutic target for PAH treatment, a study reports. The study, “Inhibition of Shp2 ameliorates monocrotaline-induced…
The U.S. Food and Drug Administration has granted orphan drug designation to Livantra, a new formulation of an already approved treatment outside the U.S. for another indication, for the treatment of pulmonary arterial hypertension (PAH), according to the…
Inhibition of proteins that regulate gene expression — called BET — were found to ease pulmonary hypertension (PH) in a rat model of chronic obstructive pulmonary disease (COPD), a study reports. The study, “Inhibition of BET Proteins Reduces Right Ventricle Hypertrophy and Pulmonary Hypertension Resulting from Combined…
A clinical trial to study a therapy that may inhibit and possibly reverse vascular remodeling in pulmonary arterial hypertension (PAH) is expected to start enrolling patients in 2019. The medicine, C76, was shown to inhibit a gene called HIF-2α and to lead to reversal of PAH in animal models. The study…
Research & DevelopmentTreatment with the approved anti-cancer medication sorafenib reversed pulmonary arterial hypertension (PAH) and cardiopulmonary remodeling (CPR) in a rat model, according to a new study. The findings suggest that a low-dose therapy with this compound may be successful in PAH treatment, the Japanese research team suggests.
A man with pulmonary hypertension, the first international patient to receive an advanced but totally artificial heart known as the CARMAT heart, recently had a healthy donor heart successfully transplanted. The announcement, made by the National Research Center for Cardiac Surgery, in Astana, Kazakhstan, was confirmed by…
Bellerophon Therapeutics recently provided an update on the clinical development of INOpulse as a treatment for pulmonary arterial hypertension (PAH), as well as for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and interstitial lung disease (PH-ILD). INOpulse is an inhaled nitric oxide treatment being developed to reduce…
